Updated:
Fogarty Institute for Innovation
Dr. Thomas Fogarty founded the Fogarty Institute for Innovation in 2004 — a nonprofit medical-device incubator that has backed over 60 healthcare startups.
Fogarty Institute for Innovation
The Fogarty Institute for Innovation was established in 2004 by Dr. Thomas Fogarty, a cardiovascular surgeon who holds more than 170 patents, notably the Fogarty balloon catheter for embolectomy. Rather than acting as a conventional investment vehicle, the Institute functions as a nonprofit medical-device accelerator and early-stage incubator, providing funding, mentorship, and lab space to healthcare startups. The Institute backs companies across medical devices, digital health, and biotechnology, with a focus on cardiovascular, laparoscopic, and neuromodulation technologies. Known portfolio companies include TransMed7 (a developer of multi-function interventional tools) and PathMaker Neurosystems (which targets motor recovery after stroke), though a full portfolio list is not maintained on the public record. The Institute's model combines direct capital deployment with operational support, typically taking equity stakes in portfolio firms. The Fogarty Institute has been based in the San Francisco Bay Area (Mountain View, Palo Alto) since inception, with additional operational roots in Sydney, Australia. The team includes a small group of advisors and executives drawn from the medical-device industry. The Institute has incubated over 60 companies, though it does not publicly disclose a current AUM or total deployment figure. In 2023, the Institute announced a partnership with the Stanford Byers Center for Biodesign, formalizing a long-standing collaboration (per public record). The Institute's nonprofit structure distinguishes it from typical family offices or venture capital firms: profits from exits are reinvested into the Institute's incubation pipeline, not returned to external limited partners. This governance model allows the Institute to take patient, long-duration positions in early-stage medical technologies without the time constraints of a traditional fund vehicle.
General information
Firm type
other
Year founded
2004
AUM
Undisclosed
Location
Region
Oceania
Country
Australia
City
Sydney
Corporate office
Sydney, Australia
Additional offices
Mountain View, United States · Palo Alto, United States
Principals
Dr. Thomas Fogarty
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at the Fogarty Institute for Innovation?
Dr. Thomas Fogarty, the founder and a prolific medical-device inventor, oversees the Institute alongside a small team of advisors and executives drawn from the medical-device industry. The Institute does not publicly disclose a CIO or investment committee structure.
How does the Fogarty Institute source proprietary deal flow?
The Institute generates deal flow primarily through Dr. Fogarty's network in cardiovascular surgery and medical-device development, as well as its partnership with Stanford Byers Center for Biodesign. It also accepts applications from early-stage healthcare startups through its website.
Is the Fogarty Institute structured as a single family office or does it operate more like a venture firm?
The Fogarty Institute for Innovation is a 501(c)(3) nonprofit organization that operates as a medical-device incubator and early-stage accelerator. It is neither a traditional single-family office nor a standalone venture capital firm; it combines charitable objectives with equity-based incubation.
Does the Fogarty Institute participate in fund commitments or only direct investments?
The Institute makes direct equity investments into early-stage portfolio companies, typically as part of its incubation program. It is not known to commit capital to external limited partnership funds.
What investment stages does the Fogarty Institute typically target?
The Institute supports early-stage healthcare startups, from seed to Series A, with a focus on proof-of-concept and early clinical-stage companies in medical devices, digital health, and biotechnology.
Does the Fogarty Institute maintain philanthropic structures, and how are they separated?
The Institute itself is a nonprofit charitable entity. All operating profits from exits are reinvested into its incubation pipeline, which aligns with its stated mission to advance medical technology — there is no separation between charitable and investment activities.
Which sectors does the Fogarty Institute explicitly avoid?
The Institute primarily invests in medical-device and healthcare-technology companies. It does not publicly exclude any sectors, but its track record concentrates on cardiovascular, laparoscopic, and neuromodulation devices, with no known activity in software-only or non-healthcare sectors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: